🇺🇸 FDA
Pipeline program

A sterile preservative-free solution with identical composition as the drug product, but without the protein.

KPL-404-C221

Phase 2 small_molecule active

Quick answer

A sterile preservative-free solution with identical composition as the drug product, but without the protein. for Sjögren’s Disease is a Phase 2 program (small_molecule) at Kiniksa Pharmaceuticals International, plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Kiniksa Pharmaceuticals International, plc
Indication
Sjögren’s Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials